These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Persistence of dimerization and enzymatic activity of epidermal growth factor receptor in the absence of epidermal growth factor. Tanner KG Biochemistry; 1997 Dec; 36(48):14889-96. PubMed ID: 9398212 [TBL] [Abstract][Full Text] [Related]
4. Kinetics of activation of the tyrosine kinase of a deletion mutant of epidermal growth factor receptor missing the sites of self-phosphorylation. Sherrill JM; Kyte J Biochemistry; 1999 Mar; 38(10):3106-11. PubMed ID: 10074364 [TBL] [Abstract][Full Text] [Related]
5. Genistein, a tyrosine kinase inhibitor, reduces EGF-induced EGF receptor internalization and degradation in human hepatoma HepG2 cells. Yang EB; Wang DF; Mack P; Cheng LY Biochem Biophys Res Commun; 1996 Jul; 224(2):309-17. PubMed ID: 8702388 [TBL] [Abstract][Full Text] [Related]
6. The protein kinase C inhibitor Go6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole] potentiates agonist-induced mitogen-activated protein kinase activation through tyrosine phosphorylation of the epidermal growth factor receptor. Shah BH; Olivares-Reyes JA; Catt KJ Mol Pharmacol; 2005 Jan; 67(1):184-94. PubMed ID: 15465928 [TBL] [Abstract][Full Text] [Related]
7. The juxtamembrane region of the epidermal growth factor receptor is required for phosphorylation of Galpha(s). Poppleton HM; Sun H; Mullenix JB; Wiepz GJ; Bertics PJ; Patel TB Arch Biochem Biophys; 2000 Nov; 383(2):309-17. PubMed ID: 11185568 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635 [TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor activates protein kinase C in the human endometrial cancer cell line HEC-1-A. Connor P; Talavera F; Kang JS; Burke J; Roberts J; Menon KM Gynecol Oncol; 1997 Oct; 67(1):46-50. PubMed ID: 9345355 [TBL] [Abstract][Full Text] [Related]
10. 5'-(p-fluorosulfonylbenzoyl)-2'(or 3')-(methylanthraniloyl)adenosine, fluorescent affinity labels for adenine nucleotide binding sites: interaction with the kinase active site of the receptor for epidermal growth factor. Scoggins RM; Summerfield AE; Stein RA; Guyer CA; Staros JV Biochemistry; 1996 Jul; 35(28):9197-203. PubMed ID: 8703925 [TBL] [Abstract][Full Text] [Related]
11. Structural and mutational analysis of affinity-inert contact residues at the growth hormone-receptor interface. Pearce KH; Ultsch MH; Kelley RF; de Vos AM; Wells JA Biochemistry; 1996 Aug; 35(32):10300-7. PubMed ID: 8756685 [TBL] [Abstract][Full Text] [Related]
12. Insufficiency of self-phosphorylation for the activation of epidermal growth factor receptor. Sherrill JM Biochemistry; 1997 May; 36(19):5677-84. PubMed ID: 9153407 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Putz T; Culig Z; Eder IE; Nessler-Menardi C; Bartsch G; Grunicke H; Uberall F; Klocker H Cancer Res; 1999 Jan; 59(1):227-33. PubMed ID: 9892211 [TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132 [TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602 [TBL] [Abstract][Full Text] [Related]
16. Activation mechanism of solubilized epidermal growth factor receptor tyrosine kinase. Ge G; Wu J; Wang Y; Lin Q Biochem Biophys Res Commun; 2002 Jan; 290(3):914-20. PubMed ID: 11798160 [TBL] [Abstract][Full Text] [Related]
17. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Matsuda K; Idezawa T; You XJ; Kothari NH; Fan H; Korc M Cancer Res; 2002 Oct; 62(19):5611-7. PubMed ID: 12359775 [TBL] [Abstract][Full Text] [Related]
18. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Johnson FM; Saigal B; Donato NJ J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238 [TBL] [Abstract][Full Text] [Related]
19. Effect of membrane fluidity on tyrosine kinase activity of reconstituted epidermal growth factor receptor. Ge G; Wu J; Lin Q Biochem Biophys Res Commun; 2001 Mar; 282(2):511-4. PubMed ID: 11401489 [TBL] [Abstract][Full Text] [Related]
20. The transmembrane protein tyrosine phosphatase RPTPsigma modulates signaling of the epidermal growth factor receptor in A431 cells. Suárez Pestana E; Tenev T; Gross S; Stoyanov B; Ogata M; Böhmer FD Oncogene; 1999 Jul; 18(28):4069-79. PubMed ID: 10435588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]